We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.58 | 27.32% | 12.00 | 10.30 | 10.80 | 10.30 | 9.20 | 9.40 | 3,770,461 | 16:46:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.34 | 25.98M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/8/2020 13:26 | I aim to please :) | toffeeman | |
24/8/2020 12:46 | Toffeeman, You actually made me laugh out loud lol I thought you were serious for a moment lol | alloa2003 | |
24/8/2020 12:00 | Stig a ramper? - Shome mishtake shurely - s/he is without doubt the most courteous and well informed poster on any bulletin board anywhere in the world. :) :) :) | toffeeman | |
24/8/2020 10:41 | Ramp ramp ramp - just let the situation speak for itself. He was using these companies as examples in the interview. You banged on for weeks about a non-existant Covid-19 deal even though Clive Dix said this was not something the company was looking at. The facts and the potential are enough to support a much higher share price, dont spoil it all with your pathetic ramping. | alloa2003 | |
24/8/2020 09:33 | Novartis Cosentyx annual sales > $3bn p.a. Eli Lilly Taltz annual sales > $1bn p.a. | the stigologist | |
24/8/2020 08:25 | I bought a few too. This is due a pop, could see 40 very quickly | shammytime | |
24/8/2020 08:16 | Iv just bought 15000 | bloomberg2 | |
24/8/2020 08:08 | Nothing available online to buy, hmmmmmmm | avsome1968 | |
21/8/2020 12:54 | Just gone long (2nd time - first time I was down 20 points when I closed) - so same again and see what happens about closing that damn gap. | toffeeman | |
21/8/2020 12:24 | DaveMac3, You could in Stig's world PMSL Everything is easy with hindsight lol | alloa2003 | |
21/8/2020 11:57 | you could never buy this at 7p | davemac3 | |
21/8/2020 11:39 | Indeed alloa. I think I'll cope though | pugg1ey | |
21/8/2020 11:32 | You really are a nasty piece of work - another coward hiding behind his keyboard. | alloa2003 | |
21/8/2020 11:16 | no. i had no money to average down. think before you post such drivel | pugg1ey | |
21/8/2020 10:33 | I am on the boat. Unfortunately at 38p. Hopefully the right news will drive me into a nice profit | pugg1ey | |
21/8/2020 10:31 | Oh dear a few bitter people have missed the boat | the stigologist | |
21/8/2020 10:20 | I suspect you are right DM3. The people they were talking to wanted more in-vivo data before becoming interested, hence the time gap The relevant studies should be all done by now. Whether they yielded the desired results will be shown if there is a deal done in the near future. | pugg1ey | |
21/8/2020 10:05 | To deter traders. still 40% plus gain from here to fill gap | avsome1968 | |
21/8/2020 10:02 | The spread is crazy! | imnotspartacus | |
21/8/2020 09:56 | from that Tweet "Now been revealed IL17 targeting Novartis and Eli Lilly." LOL nothing has been revealed, Novartis and ELi Lilly have IL17 drugs, the ramp machine is working overtime here. discussions started on the NRF2 compound probably about 18months-2 years ago, so it has been a slow process, maybe they started talking too early. | davemac3 | |
21/8/2020 09:44 | Chart is saying 100p to me but I'm wondering if long suffering shareholders who've stayed the course will be rewarded with an absolute stonker of a deal? PYC recently signed deal with 19th largest Global Pharma in the World but discussions started in Dec 2019 Timelines in this industry are looooong . So Clive can't be blamed for deals being delayed. It must require LOTS of legals and DD to get a $1bn+ deal over the line | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions